Article
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 15 Sept 2006
Ritchie Marylyn D, Haas David W, Motsinger Alison A, Donahue John P, Erdem Huso, Raffanti Stephen, Rebeiro Peter, George Alfred L, Kim Richard B, Haines Jonathan L, Sterling Timothy R
Abstract excerpt
This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenz- or nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C-->T (odds ratio, 0.254; P=.021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82% accuracy (P<.001).
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.